StockData
Biodexa Pharmaceuticals Plc logo

Biodexa Pharmaceuticals Plc (BDRX) stock

BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 1/30
$2.14−0.10 (-4.46%)

Close on Nov 17, 2026Market cap $4.83MP/E –Yield –

Biodexa Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

For fiscal 2025 it was -£5.59M. The highest annual figure on record is -£5.59M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-£5.59M–
FY2024Dec 31, 2024-£12.26M–
FY2023Dec 31, 2023-£6.83M–
FY2022Dec 31, 2022-£7.05M–
FY2021Dec 31, 2021-£6.01M–
FY2020Dec 31, 2020-£9.30M–
FY2019Dec 31, 2019-£6.49M–
FY2018Dec 31, 2018-£13.45M–
FY2017Dec 31, 2017-£12.95M–
FY2016Dec 31, 2016-£13.09M–
FY2015Dec 31, 2015-£12.42M–

More Biodexa Pharmaceuticals figures

See a number that looks wrong?